Prescription Medicines
Montesium tab. 10mg
- Product Category
- Asthma, rhinitis treatment
- Active Ingredients
- montelukast sodium
- Appearance
- Beige, rectangular film-coated tablet with rounded corners
- Reimbursement Code
- 648104340
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Montelukast sodium (USP) ............ 10.4mg (10mg as montelukast)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, magnesium stearate, opadry orange (03B63246), carnauba lead, croscarmellose sodium, hydroxypropyl cellulose
2. Effectiveness
1. Prevention and continuous treatment of asthma
2. Relieve seasonal and year-round allergic rhinitis symptoms
3. Dosage and dosage
This medication should be taken once a day. For asthma patients, take it in the evening, and for allergic rhinitis patients, the dosing time is determined according to the patient's condition.
Patients with both asthma and allergic rhinitis should take 1 tablet once a day in the evening.
<10mg tablet for asthma or allergic rhinitis>
Adults and adolescents over 15 years of age: Administer orally as montelukast, 10 mg once daily.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with hypersensitivity to this drug or its components
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Adverse reactions
1) Adolescent and adult asthma patients over 15 years of age
The safety of 10 mg of this drug was evaluated through clinical trials involving approximately 2,950 adolescent and adult patients aged 15 years or older. In placebo-controlled clinical trials, the relationship with the administered drug is not clear, but the adverse reactions that occurred more frequently in the medication group than in the placebo group with a frequency of more than 1% are as follows. :
Although the relationship with the administered drug is not clear, adverse reactions occurred more frequently in the medication group than in the placebo group, with a frequency of more than 1%.
※ Table: Refer to attached document
* When measuring ALT and AST, 1,935 patients participated in the medication group and 1,170 patients participated in the placebo group. When testing pyuria, 1,924 patients participated in the medication group and 1,159 patients participated in the placebo group.
For other adverse reactions with lower incidence, there was no difference between the treatment group and the placebo group. Cumulatively, in clinical trials of this drug, 569 patients received this drug for at least 6 months, 480 patients for 1 year, and 49 patients for 2 years. Even as the medication period was prolonged, the incidence of adverse reactions showed no significant change.
2) Pediatric asthma patients between 6 and 14 years of age
The safety of 5 mg of this drug was evaluated in a clinical trial involving 476 pediatric patients aged 6 to 14 years. Cumulatively, in the clinical trials of this drug, 289 patients received this drug for at least 6 months and 241 patients received this drug for more than 1 year.
In a double-blind clinical trial conducted for 8 weeks in pediatric patients, the incidence of adverse reactions to this drug was overall similar to the results obtained in adults. Although the relationship with the administered drug is not clear, the following adverse reactions occurred more frequently in pediatric patients in the placebo group than in pediatric patients in the placebo group, with a frequency of more than 2%. : Pharyngitis, influenza, fever, sinusitis, nausea, diarrhea, loss of appetite, otitis, viral infection and laryngitis. For adverse reactions with a lower incidence, there was no difference between the treatment group and the placebo group. Even as the medication period was prolonged, the incidence of adverse reactions showed no significant change.
In clinical trials evaluating growth rates, the safety profile of this drug was consistent with previous clinical trial results. In a 56-week double-blind trial evaluating growth rate in pediatric patients aged 6 to 8 years, the adverse reactions that had never been observed before in pediatric patients in this age group were as follows. Although the relationship with the administered drug was not clear, the adverse reactions that occurred more frequently in pediatric patients in the placebo group than in pediatric patients in the placebo group with a frequency of more than 2% were as follows. : Headache, (infectious) rhinitis, chickenpox, gastroenteritis, atopic dermatitis, acute bronchitis, dental infection, skin infection and myopia
3) Pediatric asthma patients between 2 and 5 years of age
The safety of this drug 4 mg was evaluated in a single-dose or multiple-dose study conducted on 573 pediatric patients aged 2 to 5 years. Cumulatively, in clinical trials, 426 pediatric patients aged 2 to 5 years received this drug for at least 3 months, 230 for more than 6 months, and 63 for more than 1 year. In clinical trials, 4 mg of this drug was generally well tolerated when taken once daily at bedtime. In pediatric patients between 2 and 5 years of age who received this drug, the relationship with the administered drug is not clear, but the following adverse reactions occurred more frequently in pediatric patients in the placebo group than in pediatric patients in the placebo group, with a frequency of more than 2%. : Fever, cough, abdominal pain, diarrhea, headache, runny nose, sinusitis, otitis, influenza, rash, ear pain, gastroenteritis, eczema, urticaria, chicken pox, pneumonia, dermatitis and conjunctivitis.
4) Pediatric asthma patients aged between 6 and 23 months
Safety and efficacy in pediatric asthma patients aged 6 to 12 months have not been established.
As a result of the safety evaluation of 175 pediatric patients aged 6 to 23 months, the safety profile of this drug was similar to that of adults and pediatric patients aged 2 to 14 years in a 6-week double-blind, placebo-controlled clinical trial. This drug was generally well tolerated when administered once daily at bedtime. In pediatric patients aged 6 to 23 months who received this drug, regardless of the causal relationship with the drug, adverse reactions that occurred more frequently in patients in the treatment group than in the placebo group and were reported at a frequency of more than 2% were upper respiratory tract infection, wheezing, otitis media, pharyngitis, tonsillitis, cough, and rhinitis. The incidence of adverse reactions reported at lower frequencies was similar between the placebo and treatment groups.
5) Adolescent and adult seasonal allergic rhinitis patients over 15 years of age
The safety of this drug was evaluated through clinical trials involving 2,199 adolescent and adult patients aged 15 years or older. When this drug was administered once daily in the morning or evening, it had a safety profile similar to placebo and was generally well tolerated. In placebo-controlled clinical trials, the relationship with the administered drug is not clear, but the following adverse reactions occurred more frequently in the medication group than in the placebo group with a frequency of more than 1%. : Upper respiratory infection (1.9% in treatment group, 1.5% in placebo group). The safety profile observed in the 4-week placebo-controlled clinical trial was consistent with that of the 2-week trial. In all tests, the incidence of drowsiness was similar to that of the placebo group.
6) Pediatric seasonal allergic rhinitis patients aged 2 to 14 years
The safety of this drug was evaluated in a 2-week, multicenter, double-blind, placebo-controlled, parallel-group safety study in 280 pediatric patients aged 2 to 14 years. When this drug was administered once daily in the evening, it had a safety profile similar to placebo and was generally well tolerated. In this trial, the relationship with the administered drug is not clear, but the adverse reactions that occurred more frequently in the medication group than the placebo group with a frequency of more than 2% are as follows. : Headache, otitis media, pharyngitis and upper respiratory tract infection
7) Adolescents and adults over 15 years of age with allergic rhinitis throughout the year
The safety of this drug was evaluated in two 6-week clinical trials targeting 3,357 patients with allergic rhinitis year-round in adolescents and adults aged 15 years or older, of whom 1,632 received the drug. When this drug was administered once daily, it was generally well tolerated and the safety profile was consistent with the results obtained in patients with seasonal allergic rhinitis and similar to placebo. In these two clinical trials, the relationship with the administered drug is not clear, but the adverse reactions that occurred more frequently in the medication group than the placebo group with a frequency of more than 1% are as follows. : Sinusitis, upper respiratory tract infection, sinus headache, cough, nosebleeds and increased ALT. The incidence of drowsiness was similar to that of the placebo group.
8) Patients with allergic rhinitis year-round in children aged between 6 months and 14 years
The safety of this drug in pediatric patients aged 2 to 14 years with year-round allergic rhinitis is proven by safety data in patients with seasonal allergic rhinitis of the same age. Safety in children between 6 months and 2 years of age is proven by safety and efficacy evaluation studies in asthma patients of this age, pharmacokinetics, and pharmacokinetic data in adults.
9) Integrated analysis of clinical trial results
An integrated analysis of suicidality was performed using validated assessment methods in 41 placebo-controlled clinical trials (35 studies in patients aged 15 years or older; 6 studies in pediatric patients aged 6 to 14 years). In these clinical trials, among 9,929 patients administered this drug and 7,780 patients administered placebo, suicidal thoughts were reported in one patient in the treatment group. There were no suicides, attempted suicides, or actions to prepare for them in either group.
Separately, an integrated analysis of behavior-related adverse experiences (BRAEs) was conducted in 46 placebo-controlled clinical trials (35 studies in patients aged 15 years or older; 11 studies in pediatric patients aged 3 months to 14 years). Of the 11,673 patients treated with this drug and 8,827 patients treated with placebo in these clinical trials, at least one BRAE was reported in 2.73% of patients treated with this drug and 2.27% of patients treated with placebo; The odds ratio was 1.12 (95% CI [0.93; 1.36]).
The trials included in the pooled analysis were not specifically designed to assess suicidality or BRAEs.
10) Adverse reactions reported in post-marketing surveillance
The following are additional adverse reactions reported through post-marketing surveillance.
(1) Infection: Upper respiratory tract infection
(2) Blood and lymphatic system: increased bleeding frequency, thrombocytopenia
(3) Immune system: hypersensitivity reaction (anaphylaxis, very rarely liver eosinophil infiltration)
(4) Mental system: Agitation, anxiety, depression, disorientation, attention disorder, sleep disorder and hallucinations, insomnia, memory disorder, psychomotor hyperactivity (including irritability, instability, tremor) including aggressive behavior or hostility, sleepwalking, suicidal thoughts and actions (including suicide), tics.
(5) Nervous system: Dizziness, drowsiness, paresthesia/hypoesthesia, and very rarely convulsive seizures.
(6) Cardiovascular system: palpitations
(7) Respiratory system, chest and mediastinum: epistaxis, pulmonary eosinophilia
(8) Digestive system: diarrhea, indigestion, nausea, very rarely pancreatitis, vomiting
(9) Hepato-biliary system: Increases in ALT and AST, and in very rare cases, cholestatic hepatitis, hepatocellular liver damage, and mixed liver damage have been reported, but in most cases, this drug was administered to patients with a possibility of liver disease such as alcohol consumption or other types of hepatitis, or it was due to other complex causes such as the use of other drugs.
(10) Skin and subcutaneous tissue: angioedema, bruising, erythema multiforme, erythema nodosum, itching, rash, urticaria, toxic epidermal necrolysis, mucocutaneous ocular syndrome
(11) Musculoskeletal system and connective tissue: muscle pain including joint pain and muscle cramps
(12) Kidney and urinary system: enuresis in children
(13) Whole body and administration site: Asthenia/fatigue, edema, fever
Rarely, asthma patients taking this drug may develop systemic eosinophilia and show vasculitis with the same clinical symptoms as Churg-Strauss syndrome. These symptoms can sometimes be treated with systemic corticosteroid therapy. Systemic eosinophilia is sometimes associated with decreased oral corticosteroid doses. Physicians should carefully monitor patients for the development of eosinophilia, vasoinflammatory rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy. The causal relationship between this drug and these symptoms has not been established.
11) As a result of a post-marketing use survey conducted on 1,635 people over 6 years for re-examination in Korea, the case rate of adverse reactions was 64 in 28 cases (1.7%), regardless of causal relationship. Among these, adverse reactions for which a causal relationship with this drug could not be ruled out were 6 cases (0.37%), including nausea (2 cases), edema, indigestion, alopecia, and itching. Among these, alopecia was an unexpected adverse drug reaction and was reported in 1 pediatric patient.
3. Generalism
1) This drug is not a treatment for bronchospasm that occurs during acute asthma attacks such as status asthmaticus.
2) Ensure patients carry appropriate emergency medications. This medication can be continued even during acute exacerbations of asthma.
3) The dosage of inhaled corticosteroid preparations can be gradually reduced under the supervision of a doctor, but inhaled or oral corticosteroid preparations should not be suddenly replaced with this medicine.
4) Neuropsychiatric symptoms were reported in patients who administered this drug (see section 3. Adverse Reactions). It is not known whether these symptoms are causally related to this drug. The doctor must tell the patient or guardian about these adverse reactions. Patients or guardians should notify the doctor if such changes occur.
5) This drug should not be used alone to treat exercise-induced bronchospasm. Patients whose asthma worsens after exercise should continue to use the regular dose of inhaled β-agonists for preventive purposes, and short-acting inhaled β-agonists can be used for emergency purposes.
6) Patients with hypersensitivity to aspirin should not take aspirin or non-steroidal anti-inflammatory drugs while taking this medicine. Although this drug is effective in improving airway function during asthma in patients with a history of hypersensitivity to aspirin, it has not been established whether this drug can treat bronchoconstriction induced by aspirin or nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity asthma.
7) Increased eosinophils
Rarely, asthma patients taking this drug may develop systemic eosinophilia and show vasculitis with the same clinical symptoms as Churg-Strauss syndrome. These symptoms can sometimes be treated with systemic corticosteroid therapy. Systemic eosinophilia is sometimes associated with decreased oral corticosteroid doses. Physicians should carefully monitor patients for the development of eosinophilia, vasoinflammatory rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy. The causal relationship between this drug and these symptoms has not been established (see section 3. Adverse Reactions).
4. Interaction
1) There are no reports of increased adverse reactions when this drug is administered together with other drugs commonly used for the prevention and long-term treatment of asthma. In drug interaction studies, the usual dosage of this drug did not have a clinically significant effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethisterone 1 mg/ethinyl estradiol 35 ug), terfenadine, digoxin, and warfarin.
2) Although additional drug interaction studies were not conducted, no clinically significant interactions were observed when this drug was co-administered with various commonly prescribed drugs in clinical trials. Drugs that were prescribed together during clinical trials included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory drugs, benzodiazepines, and decongestants.
3) Phenobarbital, which induces liver metabolism, reduces the AUC of montelukast measured after a single administration of 10 mg of montelukast by about 40%. No dosage adjustment of this drug is necessary, but it is advisable to conduct appropriate clinical monitoring when co-administering this drug with strong CYP-450 enzyme inducers such as phenobarbital, rifampicin, or phenytoin.
4) In vitro tests showed that montelukast is an inhibitor of CYP2C8, but in clinical trials on the interaction between this drug and rosiglitazone (a representative drug mainly metabolized into CYP2C8), it was proven that this drug does not inhibit CYP2C8 in vivo. Therefore, montelukast is not expected to inhibit the metabolism of drugs primarily metabolized by CYP2C8 (e.g., paclitaxel, rosiglitazone, repaglinide).
5) In vitro studies confirmed that montelukast is a substrate of CYP2C8, CYP2C9, and CYP3A4. A clinical trial to determine the drug interaction between this drug and gemfibrozil (an inhibitor of CYP2C8 and CYP2C9) showed that gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. It was confirmed that when itraconazole, a strong CYP3A4 inhibitor, was co-administered with gemfibrozil and this drug, the systemic exposure of this drug did not increase further. As a result of safety clinical trials in which doses higher than the approved dose of 10 mg were administered to adults (e.g., 200 mg/day for 22 weeks in adults, increased to 900 mg/day for approximately 1 week), no clinically important adverse drug reactions were observed, and the effect of gemfibrozil on the systemic exposure of this drug is not judged to have a clinically meaningful effect. Therefore, there is no need to adjust the dosage of this drug when co-administered with gemfibrozil. Based on in vitro results, this drug is not expected to have clinically significant drug interactions with other known CYP2C8 inhibitors, such as trimethoprim. In addition, when this drug and itraconazole were administered together, there was no significant increase in systemic exposure to this drug.
5. Administration to pregnant and lactating women
1) When montelukast was orally administered to rats at a dose of 400 mg/kg/day (corresponding to exposure 100 times the maximum daily oral dose AUC of adults) or to rabbits at a dose of 300 mg/kg/day (corresponding to exposure 110 times the maximum daily oral dose AUC of adults), no malformations were observed. This drug has been reported to cross the placenta after oral administration in rats and rabbits. However, there are no controlled trial results for pregnant women. Since the results of reproductive toxicity tests in animals do not always correspond to the results in humans, it should be administered to pregnant women only when the need is clearly recognized.
2) In post-marketing surveillance conducted around the world, congenital limb defects were rarely reported in children of women who took this drug during pregnancy. Most of these women took other asthma medications during pregnancy, and a causal relationship between this adverse reaction and this medication has not been established.
3) In rats, this drug was observed to pass into milk. It is not known whether this drug is excreted in human breast milk, but since many drugs pass into breast milk, caution should be exercised when administering this drug to nursing mothers.
6. Administration to children
1) The safety and effectiveness of this drug in pediatric asthma patients between the ages of 6 and 14 have been well established through clinical trials targeting patients of this age. The safety and efficacy profile in pediatric patients of this age was similar to the results seen in adults (see Section 3. Adverse Reactions).
2) The effectiveness of this drug for pediatric seasonal allergic rhinitis patients aged 2 to 14 years and year-round allergic rhinitis patients aged 6 months to 14 years was extrapolated from the effectiveness established in allergic rhinitis patients aged 15 years or older, and was based on the assumption that the course of the disease, pathophysiology, and drug efficacy are fundamentally similar between these patient groups.
3) The safety of this drug 4 mg chewable tablet has been well established through clinical trials targeting pediatric asthma patients aged 2 to 5 years (see section 3. Adverse Reactions). The efficacy of this drug for this age group was extrapolated from the efficacy demonstrated in patients with asthma over 6 years of age and was based on the assumption that the course of the disease, pathophysiology, and drug efficacy are fundamentally similar in this patient group, and on mutually similar pharmacokinetic data. The efficacy of this drug was proven by exploratory efficacy evaluation data obtained from a large-scale safety trial in patients aged 2 to 5 years.
4) The safety of this drug 4 mg fine granule was evaluated in 175 pediatric asthma patients aged between 6 and 23 months. Safety information for this patient group was similar to that for adults, patients over 2 years of age, and the placebo group (see section 3. Adverse Reactions). The efficacy of this drug in pediatric patients aged 6 to 23 months was extrapolated from the efficacy established in asthma patients aged 6 years and older and was based on the assumption that the course of the disease, pathophysiology, and drug efficacy are fundamentally similar in these patient groups and on mutually similar pharmacokinetic data.
5) The safety of 4 mg and 5 mg tablets of this drug for allergic rhinitis patients aged 2 to 14 years was proven in clinical trial data on asthma patients of the same age group. Safety studies in patients with seasonal allergic rhinitis in this age group showed a similar safety profile (see section 3, Adverse Reactions).
The safety of this drug 4 mg granule in patients with year-round allergic rhinitis for patients aged 6 months or older was extrapolated from safety data from clinical trials in pediatric asthma patients aged 6 to 23 months and pharmacokinetic data comparing systemic exposure in adults with systemic exposure in pediatric patients aged 6 to 23 months.
6) Two controlled clinical trials have proven that this drug does not affect the growth rate of pre-adolescent children with asthma.
7) This drug was tested clinically on pediatric patients aged 6 months to 14 years. Safety and effectiveness in pediatric asthma patients under 12 months of age and year-round allergic rhinitis in children under 6 months of age have not been established.
7. Administration to elderly people
Of the total clinical trial subjects for this drug, 3.5% were over 65 years of age, and 0.4% were over 75 years of age. No overall differences in safety or efficacy were observed between older and younger patient groups, and no other clinical differences were reported. However, the possibility that responsiveness to this drug may be increased in the elderly cannot be ruled out.
8. Treatment in case of overdose
1) When montelukast is administered orally once to mice at a dose of 5,000 mg/kg (corresponding to exposures 335 and 210 times the maximum daily oral dose AUC for adults and children, respectively), it is to be administered once orally to rats at doses up to 5,000 mg/kg (corresponding to exposures 230 and 145 times the maximum daily oral dose AUC for adults and children, respectively). At this time, no animals were killed.
2) There is no specific treatment that can be used in case of overdose of this drug. No clinically important adverse reactions were observed when patients were administered montelukast at doses up to 200 mg per day for 22 weeks in a long-term asthma study, or when patients were administered montelukast at doses up to 900 mg per day for one week in a short-term study. In case of overdose, it is reasonable to administer general symptomatic treatment (e.g., remove unabsorbed drug from the gastrointestinal tract, conduct clinical monitoring, and provide auxiliary treatment if necessary).
3) In post-marketing surveillance and clinical trials, it was reported that adults and children overdosed up to 1,000 mg of this drug, but the observed clinical symptoms or clinical test results did not differ from the safety information for adult and pediatric patients. The most reported adverse reactions were abdominal pain, drowsiness, thirst, headache, vomiting, and psychomotor hyperactivity, and were consistent with the safety information of this drug.
4) It is not known whether this drug is removed by peritoneal dialysis or hemodialysis.
9. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
10. Pharmaceutical equivalence test information
A. The test drug Asruca tablets 10 mg (Montelukast sodium) (Boryung Pharmaceutical Co., Ltd.) and the reference drug Singulair tablets 10 mg (Monterukast sodium) (MSD Korea Ltd.) were administered orally once on an empty stomach to healthy adults in a 2 When subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
※ Table: Refer to attached document
Note 1. This drug was manufactured by Boryung Pharmaceutical Co., Ltd. with the entire process using the same raw materials as Asruca Tablet 10mg (monterukast sodium) and the same manufacturing method.
11. Others
Information for Patients
1) This medicine should be taken daily as prescribed, not only during periods when asthma worsens but also during periods when there are no symptoms. If asthma is not well controlled, consult with your doctor.
2) This drug is not a treatment for acute asthma attacks. Be sure to carry an appropriate short-acting inhaled β-agonist in preparation for worsening asthma.
3) While taking this medicine, if you need to take a short-acting inhaled bronchodilator more frequently than usual, or if you need to inhale more than the maximum prescribed number of short-acting bronchodilators per day, consult a doctor.
4) Unless instructed to do so by a doctor, do not reduce the dosage or stop taking other asthma medications while taking this medication.
5) In the case of patients with exercise-induced asthma, the usual dose of inhaled β-agonist should be continued to be used for preventive purposes, unless otherwise instructed by the doctor. Additionally, all patients should carry a short-acting inhaled β-agonist for emergency use.
6) If neuropsychiatric symptoms occur while taking this medicine, the patient should notify the doctor.
7) For patients with hypersensitivity to aspirin, do not take aspirin or non-steroidal anti-inflammatory drugs while taking this medicine.
5. How to save
Store at room temperature (1~30℃) in an airtight container, avoiding moisture and light.
6. Packaging unit
28 tablets (7 tablets/PTP
7. Period of use
36 months from date of manufacture
- Active ingredient: Montelukast sodium (USP) ............ 10.4mg (10mg as montelukast)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, magnesium stearate, opadry orange (03B63246), carnauba lead, croscarmellose sodium, hydroxypropyl cellulose
2. Effectiveness
1. Prevention and continuous treatment of asthma
2. Relieve seasonal and year-round allergic rhinitis symptoms
3. Dosage and dosage
This medication should be taken once a day. For asthma patients, take it in the evening, and for allergic rhinitis patients, the dosing time is determined according to the patient's condition.
Patients with both asthma and allergic rhinitis should take 1 tablet once a day in the evening.
<10mg tablet for asthma or allergic rhinitis>
Adults and adolescents over 15 years of age: Administer orally as montelukast, 10 mg once daily.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with hypersensitivity to this drug or its components
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Adverse reactions
1) Adolescent and adult asthma patients over 15 years of age
The safety of 10 mg of this drug was evaluated through clinical trials involving approximately 2,950 adolescent and adult patients aged 15 years or older. In placebo-controlled clinical trials, the relationship with the administered drug is not clear, but the adverse reactions that occurred more frequently in the medication group than in the placebo group with a frequency of more than 1% are as follows. :
Although the relationship with the administered drug is not clear, adverse reactions occurred more frequently in the medication group than in the placebo group, with a frequency of more than 1%.
※ Table: Refer to attached document
* When measuring ALT and AST, 1,935 patients participated in the medication group and 1,170 patients participated in the placebo group. When testing pyuria, 1,924 patients participated in the medication group and 1,159 patients participated in the placebo group.
For other adverse reactions with lower incidence, there was no difference between the treatment group and the placebo group. Cumulatively, in clinical trials of this drug, 569 patients received this drug for at least 6 months, 480 patients for 1 year, and 49 patients for 2 years. Even as the medication period was prolonged, the incidence of adverse reactions showed no significant change.
2) Pediatric asthma patients between 6 and 14 years of age
The safety of 5 mg of this drug was evaluated in a clinical trial involving 476 pediatric patients aged 6 to 14 years. Cumulatively, in the clinical trials of this drug, 289 patients received this drug for at least 6 months and 241 patients received this drug for more than 1 year.
In a double-blind clinical trial conducted for 8 weeks in pediatric patients, the incidence of adverse reactions to this drug was overall similar to the results obtained in adults. Although the relationship with the administered drug is not clear, the following adverse reactions occurred more frequently in pediatric patients in the placebo group than in pediatric patients in the placebo group, with a frequency of more than 2%. : Pharyngitis, influenza, fever, sinusitis, nausea, diarrhea, loss of appetite, otitis, viral infection and laryngitis. For adverse reactions with a lower incidence, there was no difference between the treatment group and the placebo group. Even as the medication period was prolonged, the incidence of adverse reactions showed no significant change.
In clinical trials evaluating growth rates, the safety profile of this drug was consistent with previous clinical trial results. In a 56-week double-blind trial evaluating growth rate in pediatric patients aged 6 to 8 years, the adverse reactions that had never been observed before in pediatric patients in this age group were as follows. Although the relationship with the administered drug was not clear, the adverse reactions that occurred more frequently in pediatric patients in the placebo group than in pediatric patients in the placebo group with a frequency of more than 2% were as follows. : Headache, (infectious) rhinitis, chickenpox, gastroenteritis, atopic dermatitis, acute bronchitis, dental infection, skin infection and myopia
3) Pediatric asthma patients between 2 and 5 years of age
The safety of this drug 4 mg was evaluated in a single-dose or multiple-dose study conducted on 573 pediatric patients aged 2 to 5 years. Cumulatively, in clinical trials, 426 pediatric patients aged 2 to 5 years received this drug for at least 3 months, 230 for more than 6 months, and 63 for more than 1 year. In clinical trials, 4 mg of this drug was generally well tolerated when taken once daily at bedtime. In pediatric patients between 2 and 5 years of age who received this drug, the relationship with the administered drug is not clear, but the following adverse reactions occurred more frequently in pediatric patients in the placebo group than in pediatric patients in the placebo group, with a frequency of more than 2%. : Fever, cough, abdominal pain, diarrhea, headache, runny nose, sinusitis, otitis, influenza, rash, ear pain, gastroenteritis, eczema, urticaria, chicken pox, pneumonia, dermatitis and conjunctivitis.
4) Pediatric asthma patients aged between 6 and 23 months
Safety and efficacy in pediatric asthma patients aged 6 to 12 months have not been established.
As a result of the safety evaluation of 175 pediatric patients aged 6 to 23 months, the safety profile of this drug was similar to that of adults and pediatric patients aged 2 to 14 years in a 6-week double-blind, placebo-controlled clinical trial. This drug was generally well tolerated when administered once daily at bedtime. In pediatric patients aged 6 to 23 months who received this drug, regardless of the causal relationship with the drug, adverse reactions that occurred more frequently in patients in the treatment group than in the placebo group and were reported at a frequency of more than 2% were upper respiratory tract infection, wheezing, otitis media, pharyngitis, tonsillitis, cough, and rhinitis. The incidence of adverse reactions reported at lower frequencies was similar between the placebo and treatment groups.
5) Adolescent and adult seasonal allergic rhinitis patients over 15 years of age
The safety of this drug was evaluated through clinical trials involving 2,199 adolescent and adult patients aged 15 years or older. When this drug was administered once daily in the morning or evening, it had a safety profile similar to placebo and was generally well tolerated. In placebo-controlled clinical trials, the relationship with the administered drug is not clear, but the following adverse reactions occurred more frequently in the medication group than in the placebo group with a frequency of more than 1%. : Upper respiratory infection (1.9% in treatment group, 1.5% in placebo group). The safety profile observed in the 4-week placebo-controlled clinical trial was consistent with that of the 2-week trial. In all tests, the incidence of drowsiness was similar to that of the placebo group.
6) Pediatric seasonal allergic rhinitis patients aged 2 to 14 years
The safety of this drug was evaluated in a 2-week, multicenter, double-blind, placebo-controlled, parallel-group safety study in 280 pediatric patients aged 2 to 14 years. When this drug was administered once daily in the evening, it had a safety profile similar to placebo and was generally well tolerated. In this trial, the relationship with the administered drug is not clear, but the adverse reactions that occurred more frequently in the medication group than the placebo group with a frequency of more than 2% are as follows. : Headache, otitis media, pharyngitis and upper respiratory tract infection
7) Adolescents and adults over 15 years of age with allergic rhinitis throughout the year
The safety of this drug was evaluated in two 6-week clinical trials targeting 3,357 patients with allergic rhinitis year-round in adolescents and adults aged 15 years or older, of whom 1,632 received the drug. When this drug was administered once daily, it was generally well tolerated and the safety profile was consistent with the results obtained in patients with seasonal allergic rhinitis and similar to placebo. In these two clinical trials, the relationship with the administered drug is not clear, but the adverse reactions that occurred more frequently in the medication group than the placebo group with a frequency of more than 1% are as follows. : Sinusitis, upper respiratory tract infection, sinus headache, cough, nosebleeds and increased ALT. The incidence of drowsiness was similar to that of the placebo group.
8) Patients with allergic rhinitis year-round in children aged between 6 months and 14 years
The safety of this drug in pediatric patients aged 2 to 14 years with year-round allergic rhinitis is proven by safety data in patients with seasonal allergic rhinitis of the same age. Safety in children between 6 months and 2 years of age is proven by safety and efficacy evaluation studies in asthma patients of this age, pharmacokinetics, and pharmacokinetic data in adults.
9) Integrated analysis of clinical trial results
An integrated analysis of suicidality was performed using validated assessment methods in 41 placebo-controlled clinical trials (35 studies in patients aged 15 years or older; 6 studies in pediatric patients aged 6 to 14 years). In these clinical trials, among 9,929 patients administered this drug and 7,780 patients administered placebo, suicidal thoughts were reported in one patient in the treatment group. There were no suicides, attempted suicides, or actions to prepare for them in either group.
Separately, an integrated analysis of behavior-related adverse experiences (BRAEs) was conducted in 46 placebo-controlled clinical trials (35 studies in patients aged 15 years or older; 11 studies in pediatric patients aged 3 months to 14 years). Of the 11,673 patients treated with this drug and 8,827 patients treated with placebo in these clinical trials, at least one BRAE was reported in 2.73% of patients treated with this drug and 2.27% of patients treated with placebo; The odds ratio was 1.12 (95% CI [0.93; 1.36]).
The trials included in the pooled analysis were not specifically designed to assess suicidality or BRAEs.
10) Adverse reactions reported in post-marketing surveillance
The following are additional adverse reactions reported through post-marketing surveillance.
(1) Infection: Upper respiratory tract infection
(2) Blood and lymphatic system: increased bleeding frequency, thrombocytopenia
(3) Immune system: hypersensitivity reaction (anaphylaxis, very rarely liver eosinophil infiltration)
(4) Mental system: Agitation, anxiety, depression, disorientation, attention disorder, sleep disorder and hallucinations, insomnia, memory disorder, psychomotor hyperactivity (including irritability, instability, tremor) including aggressive behavior or hostility, sleepwalking, suicidal thoughts and actions (including suicide), tics.
(5) Nervous system: Dizziness, drowsiness, paresthesia/hypoesthesia, and very rarely convulsive seizures.
(6) Cardiovascular system: palpitations
(7) Respiratory system, chest and mediastinum: epistaxis, pulmonary eosinophilia
(8) Digestive system: diarrhea, indigestion, nausea, very rarely pancreatitis, vomiting
(9) Hepato-biliary system: Increases in ALT and AST, and in very rare cases, cholestatic hepatitis, hepatocellular liver damage, and mixed liver damage have been reported, but in most cases, this drug was administered to patients with a possibility of liver disease such as alcohol consumption or other types of hepatitis, or it was due to other complex causes such as the use of other drugs.
(10) Skin and subcutaneous tissue: angioedema, bruising, erythema multiforme, erythema nodosum, itching, rash, urticaria, toxic epidermal necrolysis, mucocutaneous ocular syndrome
(11) Musculoskeletal system and connective tissue: muscle pain including joint pain and muscle cramps
(12) Kidney and urinary system: enuresis in children
(13) Whole body and administration site: Asthenia/fatigue, edema, fever
Rarely, asthma patients taking this drug may develop systemic eosinophilia and show vasculitis with the same clinical symptoms as Churg-Strauss syndrome. These symptoms can sometimes be treated with systemic corticosteroid therapy. Systemic eosinophilia is sometimes associated with decreased oral corticosteroid doses. Physicians should carefully monitor patients for the development of eosinophilia, vasoinflammatory rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy. The causal relationship between this drug and these symptoms has not been established.
11) As a result of a post-marketing use survey conducted on 1,635 people over 6 years for re-examination in Korea, the case rate of adverse reactions was 64 in 28 cases (1.7%), regardless of causal relationship. Among these, adverse reactions for which a causal relationship with this drug could not be ruled out were 6 cases (0.37%), including nausea (2 cases), edema, indigestion, alopecia, and itching. Among these, alopecia was an unexpected adverse drug reaction and was reported in 1 pediatric patient.
3. Generalism
1) This drug is not a treatment for bronchospasm that occurs during acute asthma attacks such as status asthmaticus.
2) Ensure patients carry appropriate emergency medications. This medication can be continued even during acute exacerbations of asthma.
3) The dosage of inhaled corticosteroid preparations can be gradually reduced under the supervision of a doctor, but inhaled or oral corticosteroid preparations should not be suddenly replaced with this medicine.
4) Neuropsychiatric symptoms were reported in patients who administered this drug (see section 3. Adverse Reactions). It is not known whether these symptoms are causally related to this drug. The doctor must tell the patient or guardian about these adverse reactions. Patients or guardians should notify the doctor if such changes occur.
5) This drug should not be used alone to treat exercise-induced bronchospasm. Patients whose asthma worsens after exercise should continue to use the regular dose of inhaled β-agonists for preventive purposes, and short-acting inhaled β-agonists can be used for emergency purposes.
6) Patients with hypersensitivity to aspirin should not take aspirin or non-steroidal anti-inflammatory drugs while taking this medicine. Although this drug is effective in improving airway function during asthma in patients with a history of hypersensitivity to aspirin, it has not been established whether this drug can treat bronchoconstriction induced by aspirin or nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity asthma.
7) Increased eosinophils
Rarely, asthma patients taking this drug may develop systemic eosinophilia and show vasculitis with the same clinical symptoms as Churg-Strauss syndrome. These symptoms can sometimes be treated with systemic corticosteroid therapy. Systemic eosinophilia is sometimes associated with decreased oral corticosteroid doses. Physicians should carefully monitor patients for the development of eosinophilia, vasoinflammatory rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy. The causal relationship between this drug and these symptoms has not been established (see section 3. Adverse Reactions).
4. Interaction
1) There are no reports of increased adverse reactions when this drug is administered together with other drugs commonly used for the prevention and long-term treatment of asthma. In drug interaction studies, the usual dosage of this drug did not have a clinically significant effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethisterone 1 mg/ethinyl estradiol 35 ug), terfenadine, digoxin, and warfarin.
2) Although additional drug interaction studies were not conducted, no clinically significant interactions were observed when this drug was co-administered with various commonly prescribed drugs in clinical trials. Drugs that were prescribed together during clinical trials included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory drugs, benzodiazepines, and decongestants.
3) Phenobarbital, which induces liver metabolism, reduces the AUC of montelukast measured after a single administration of 10 mg of montelukast by about 40%. No dosage adjustment of this drug is necessary, but it is advisable to conduct appropriate clinical monitoring when co-administering this drug with strong CYP-450 enzyme inducers such as phenobarbital, rifampicin, or phenytoin.
4) In vitro tests showed that montelukast is an inhibitor of CYP2C8, but in clinical trials on the interaction between this drug and rosiglitazone (a representative drug mainly metabolized into CYP2C8), it was proven that this drug does not inhibit CYP2C8 in vivo. Therefore, montelukast is not expected to inhibit the metabolism of drugs primarily metabolized by CYP2C8 (e.g., paclitaxel, rosiglitazone, repaglinide).
5) In vitro studies confirmed that montelukast is a substrate of CYP2C8, CYP2C9, and CYP3A4. A clinical trial to determine the drug interaction between this drug and gemfibrozil (an inhibitor of CYP2C8 and CYP2C9) showed that gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. It was confirmed that when itraconazole, a strong CYP3A4 inhibitor, was co-administered with gemfibrozil and this drug, the systemic exposure of this drug did not increase further. As a result of safety clinical trials in which doses higher than the approved dose of 10 mg were administered to adults (e.g., 200 mg/day for 22 weeks in adults, increased to 900 mg/day for approximately 1 week), no clinically important adverse drug reactions were observed, and the effect of gemfibrozil on the systemic exposure of this drug is not judged to have a clinically meaningful effect. Therefore, there is no need to adjust the dosage of this drug when co-administered with gemfibrozil. Based on in vitro results, this drug is not expected to have clinically significant drug interactions with other known CYP2C8 inhibitors, such as trimethoprim. In addition, when this drug and itraconazole were administered together, there was no significant increase in systemic exposure to this drug.
5. Administration to pregnant and lactating women
1) When montelukast was orally administered to rats at a dose of 400 mg/kg/day (corresponding to exposure 100 times the maximum daily oral dose AUC of adults) or to rabbits at a dose of 300 mg/kg/day (corresponding to exposure 110 times the maximum daily oral dose AUC of adults), no malformations were observed. This drug has been reported to cross the placenta after oral administration in rats and rabbits. However, there are no controlled trial results for pregnant women. Since the results of reproductive toxicity tests in animals do not always correspond to the results in humans, it should be administered to pregnant women only when the need is clearly recognized.
2) In post-marketing surveillance conducted around the world, congenital limb defects were rarely reported in children of women who took this drug during pregnancy. Most of these women took other asthma medications during pregnancy, and a causal relationship between this adverse reaction and this medication has not been established.
3) In rats, this drug was observed to pass into milk. It is not known whether this drug is excreted in human breast milk, but since many drugs pass into breast milk, caution should be exercised when administering this drug to nursing mothers.
6. Administration to children
1) The safety and effectiveness of this drug in pediatric asthma patients between the ages of 6 and 14 have been well established through clinical trials targeting patients of this age. The safety and efficacy profile in pediatric patients of this age was similar to the results seen in adults (see Section 3. Adverse Reactions).
2) The effectiveness of this drug for pediatric seasonal allergic rhinitis patients aged 2 to 14 years and year-round allergic rhinitis patients aged 6 months to 14 years was extrapolated from the effectiveness established in allergic rhinitis patients aged 15 years or older, and was based on the assumption that the course of the disease, pathophysiology, and drug efficacy are fundamentally similar between these patient groups.
3) The safety of this drug 4 mg chewable tablet has been well established through clinical trials targeting pediatric asthma patients aged 2 to 5 years (see section 3. Adverse Reactions). The efficacy of this drug for this age group was extrapolated from the efficacy demonstrated in patients with asthma over 6 years of age and was based on the assumption that the course of the disease, pathophysiology, and drug efficacy are fundamentally similar in this patient group, and on mutually similar pharmacokinetic data. The efficacy of this drug was proven by exploratory efficacy evaluation data obtained from a large-scale safety trial in patients aged 2 to 5 years.
4) The safety of this drug 4 mg fine granule was evaluated in 175 pediatric asthma patients aged between 6 and 23 months. Safety information for this patient group was similar to that for adults, patients over 2 years of age, and the placebo group (see section 3. Adverse Reactions). The efficacy of this drug in pediatric patients aged 6 to 23 months was extrapolated from the efficacy established in asthma patients aged 6 years and older and was based on the assumption that the course of the disease, pathophysiology, and drug efficacy are fundamentally similar in these patient groups and on mutually similar pharmacokinetic data.
5) The safety of 4 mg and 5 mg tablets of this drug for allergic rhinitis patients aged 2 to 14 years was proven in clinical trial data on asthma patients of the same age group. Safety studies in patients with seasonal allergic rhinitis in this age group showed a similar safety profile (see section 3, Adverse Reactions).
The safety of this drug 4 mg granule in patients with year-round allergic rhinitis for patients aged 6 months or older was extrapolated from safety data from clinical trials in pediatric asthma patients aged 6 to 23 months and pharmacokinetic data comparing systemic exposure in adults with systemic exposure in pediatric patients aged 6 to 23 months.
6) Two controlled clinical trials have proven that this drug does not affect the growth rate of pre-adolescent children with asthma.
7) This drug was tested clinically on pediatric patients aged 6 months to 14 years. Safety and effectiveness in pediatric asthma patients under 12 months of age and year-round allergic rhinitis in children under 6 months of age have not been established.
7. Administration to elderly people
Of the total clinical trial subjects for this drug, 3.5% were over 65 years of age, and 0.4% were over 75 years of age. No overall differences in safety or efficacy were observed between older and younger patient groups, and no other clinical differences were reported. However, the possibility that responsiveness to this drug may be increased in the elderly cannot be ruled out.
8. Treatment in case of overdose
1) When montelukast is administered orally once to mice at a dose of 5,000 mg/kg (corresponding to exposures 335 and 210 times the maximum daily oral dose AUC for adults and children, respectively), it is to be administered once orally to rats at doses up to 5,000 mg/kg (corresponding to exposures 230 and 145 times the maximum daily oral dose AUC for adults and children, respectively). At this time, no animals were killed.
2) There is no specific treatment that can be used in case of overdose of this drug. No clinically important adverse reactions were observed when patients were administered montelukast at doses up to 200 mg per day for 22 weeks in a long-term asthma study, or when patients were administered montelukast at doses up to 900 mg per day for one week in a short-term study. In case of overdose, it is reasonable to administer general symptomatic treatment (e.g., remove unabsorbed drug from the gastrointestinal tract, conduct clinical monitoring, and provide auxiliary treatment if necessary).
3) In post-marketing surveillance and clinical trials, it was reported that adults and children overdosed up to 1,000 mg of this drug, but the observed clinical symptoms or clinical test results did not differ from the safety information for adult and pediatric patients. The most reported adverse reactions were abdominal pain, drowsiness, thirst, headache, vomiting, and psychomotor hyperactivity, and were consistent with the safety information of this drug.
4) It is not known whether this drug is removed by peritoneal dialysis or hemodialysis.
9. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
10. Pharmaceutical equivalence test information
A. The test drug Asruca tablets 10 mg (Montelukast sodium) (Boryung Pharmaceutical Co., Ltd.) and the reference drug Singulair tablets 10 mg (Monterukast sodium) (MSD Korea Ltd.) were administered orally once on an empty stomach to healthy adults in a 2 When subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
※ Table: Refer to attached document
Note 1. This drug was manufactured by Boryung Pharmaceutical Co., Ltd. with the entire process using the same raw materials as Asruca Tablet 10mg (monterukast sodium) and the same manufacturing method.
11. Others
Information for Patients
1) This medicine should be taken daily as prescribed, not only during periods when asthma worsens but also during periods when there are no symptoms. If asthma is not well controlled, consult with your doctor.
2) This drug is not a treatment for acute asthma attacks. Be sure to carry an appropriate short-acting inhaled β-agonist in preparation for worsening asthma.
3) While taking this medicine, if you need to take a short-acting inhaled bronchodilator more frequently than usual, or if you need to inhale more than the maximum prescribed number of short-acting bronchodilators per day, consult a doctor.
4) Unless instructed to do so by a doctor, do not reduce the dosage or stop taking other asthma medications while taking this medication.
5) In the case of patients with exercise-induced asthma, the usual dose of inhaled β-agonist should be continued to be used for preventive purposes, unless otherwise instructed by the doctor. Additionally, all patients should carry a short-acting inhaled β-agonist for emergency use.
6) If neuropsychiatric symptoms occur while taking this medicine, the patient should notify the doctor.
7) For patients with hypersensitivity to aspirin, do not take aspirin or non-steroidal anti-inflammatory drugs while taking this medicine.
5. How to save
Store at room temperature (1~30℃) in an airtight container, avoiding moisture and light.
6. Packaging unit
28 tablets (7 tablets/PTP
7. Period of use
36 months from date of manufacture